Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
24 July 2020Website:
http://www.annexonbio.comNext earnings report:
26 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 3 min agoDividend
Analysts recommendations
Institutional Ownership
ANNX Latest News
BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to seven new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on November 12, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Enhanced protection of vision with ANX007 treatment in healthier eyes Greater preservation of EZ in the central fovea by ANX007 in patients with less advanced GA Pivotal Phase 3 ARCHER II Data Expected Second Half 2026 BRISBANE, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on upstream C1q to advance therapies for neuroinflammatory diseases of the body, brain and eye, today announced new findings from its Phase 2 ARCHER study for ANX007 in geographic atrophy (GA) due to dry age-related macular degeneration (AMD).
On October 1, 2024, Director William Carson purchased 3,200 shares of Annexon Inc (ANNX, Financial), as reported in a recent SEC Filing. The transaction occurred at a price of $5.97 per share, totaling $19,104.
Annexon's ANX005 shows promise for GBS. Phase 3 trial results indicate expedited recovery and durable benefits. ANNX targets the classical complement pathway, specifically the C1q protein, to address autoimmune, neurodegenerative, and ophthalmic conditions. The company's pipeline includes ANX005, ANX007, and ANX1502. Due to its advanced development stage, ANX005 is the primary value driver.
BRISBANE, Calif., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain and eye, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on August 15, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
BRISBANE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing novel therapies for neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on July 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation
After losing some value lately, a hammer chart pattern has been formed for Annexon (ANNX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints
Here is how Annexon, Inc. (ANNX) and Avalo Therapeutics, Inc. (AVTX) have performed compared to their sector so far this year.
- 1(current)
What type of business is Annexon?
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
What sector is Annexon in?
Annexon is in the Healthcare sector
What industry is Annexon in?
Annexon is in the Biotechnology industry
What country is Annexon from?
Annexon is headquartered in United States
When did Annexon go public?
Annexon initial public offering (IPO) was on 24 July 2020
What is Annexon website?
https://www.annexonbio.com
Is Annexon in the S&P 500?
No, Annexon is not included in the S&P 500 index
Is Annexon in the NASDAQ 100?
No, Annexon is not included in the NASDAQ 100 index
Is Annexon in the Dow Jones?
No, Annexon is not included in the Dow Jones index
When was Annexon the previous earnings report?
No data
When does Annexon earnings report?
The next expected earnings date for Annexon is 26 March 2025